FUNDAMENTALS · Fundamentals · US Healthcare

Genprex (GNPX) Fundamentals 2026 — Revenue Analysis | SniperIQ

Genprex (GNPX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4M, trading at $8.26 on the NASDAQ. This SniperIQ fundamentals page covers Genprex's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$4M
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Genprex's market cap?

Genprex (GNPX) has a market capitalization of approximately $4M, trading at $8.26 on the NASDAQ. Market cap moves with the live share price.

What is Genprex's P/E ratio?

Genprex's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Genprex?

Genprex runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Genprex pay a dividend?

Genprex does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Genprex financially healthy?

Genprex carries a debt-to-equity ratio of 0.00x and a current ratio of 5.61x, with a market beta of -0.91. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Genprex a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Genprex (GNPX) the key facts are: market cap $4M, 52-week range 6.715-1210. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Genprex's full fundamentals live

Get Genprex's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Alzamend Neuro (ALZN) fundamentals · PharmaCyte Biotech (PMCB) fundamentals · Addex Therapeutics (ADXN) fundamentals · CollPlant Biotechnologies (CLGN) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons